Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C06 Status

Figure 1

The HLA-C06 phenotype in psoriatic disease. Patients carrying this genetic biomarker showed more severe and widespread skin disease, a younger age at disease onset, and more family history of disease (type I disease). As a novel finding, these patients had less hypertension and lower BMI as well as lower waist perimeter, thus showing a better cardiometabolic profile. Finally, this biomarker does not seem useful to identify PsA. BMI: body mass index; PsA: psoriatic arthritis.